| Drug Name |
Atazanavir sulfate |
| Drug ID |
BADD_D00177 |
| Description |
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. |
| Indications and Usage |
Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
J05AE08 |
| DrugBank ID |
DB01072
|
| KEGG ID |
D01276
|
| MeSH ID |
D000069446
|
| PubChem ID |
158550
|
| TTD Drug ID |
D07IQS
|
| NDC Product Code |
66406-0286; 62207-005; 66406-0287; 68554-0055; 17337-0009; 65015-851; 53104-7682; 68554-0101; 54245-7031; 65015-678; 50370-0049; 50193-3264; 51407-172; 52562-008; 69037-0063; 0093-5526; 0093-5527; 0093-5528; 65862-701; 65675-1003; 66406-0288 |
| Synonyms |
Atazanavir Sulfate | Reyataz | Atazanavir | 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester | CGP 75176 | CGP75176 | CGP-75176 | CGP 73547 | CGP-73547 | CGP73547 | CGP 75355 | CGP75355 | CGP-75355 | CGP 75136 | CGP75136 | CGP-75136 | BMS-232632-05 | BMS 232632 05 | BMS23263205 | BMS 232632 | 232632, BMS | BMS-232632 | BMS232632 |
